News from neurosigma A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 26, 2014, 18:45 ET

NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering

 NeuroSigma, Inc., a Los Angeles-based life sciences company established to develop bioelectronic technologies, today announced that it has...

Aug 25, 2014, 07:00 ET

U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™...

Jul 22, 2014, 07:00 ET

Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jul 09, 2014, 07:00 ET

NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jul 08, 2014, 07:00 ET

Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jun 03, 2014, 07:00 ET

Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Apr 01, 2014, 07:00 ET

NeuroSigma Receives Approval from Australian Therapeutic Goods Administration to Market its Monarch™ eTNS™ System for the Adjunctive Treatment of Drug-Resistant Epilepsy

 NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System...

Mar 28, 2014, 07:00 ET

NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Feb 25, 2014, 07:00 ET

David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Feb 11, 2014, 06:00 ET

Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jan 27, 2014, 06:00 ET

Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™...

Jan 21, 2014, 05:00 ET

External Trigeminal Nerve Stimulation (eTNS) Presentations at the American Epilepsy Society Meeting

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, today announced that two presentations were made last month at the...

Dec 05, 2013, 07:00 ET

NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, announced today that the U.S. Patent and Trademark Office...

Jul 29, 2013, 08:00 ET

NeuroSigma Announces FDA Approval to Commence Phase III Trial

 NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration (FDA) of its Investigational Device Exemption...

Jun 21, 2013, 06:00 ET

NeuroSigma Announces Debut of Its Monarch eTNS System in Canada

 NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch™ eTNS™ System for the adjunctive...

Jun 06, 2013, 07:00 ET

NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression

 NeuroSigma, Inc., a California-based medical device company, today announced the launch of www.monarch-etns.com, its dedicated website for the...

May 20, 2013, 17:00 ET

Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)

Today, at the American Psychiatric Association (APA) Meeting in San Francisco, James McGough, M.D., M.S., principal investigator and Professor of...

May 02, 2013, 06:00 ET
The eTNS System.  (PRNewsFoto/NeuroSigma, Inc.)

NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder

NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its...

Apr 18, 2013, 03:01 ET

Results of Pediatric Clinical Trial of External Trigeminal Nerve Stimulation for the Treatment of ADHD

 NeuroSigma, Inc., a California-based medical device company, today announced that the results of the first-ever pediatric clinical trial of...

Mar 25, 2013, 03:01 ET

External Trigeminal Nerve Stimulation (eTNS) For Refractory Status Epilepticus

NeuroSigma, Inc., a California-based medical device company, today announced that it will exhibit its CE Mark approved, non-invasive Monarch™...